Open an account

Gyre Therapeutics

GYRE · NASDAQ

$6.17+$0.08 (+1.31%)TodayMarket closed ·
Prev close $6.09

About GYRE

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 618 full-time employees. The company went IPO on 2006-04-12. The company is also advancing a diverse pipeline in the PRC through its controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY, and development programs for F573, and F528. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. The company is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. The company is also focused on commercializing the avatrombopag product and discovery and development of targeted protein degrader and degrader antibody conjugate therapies.

Employees
618
Headquarters
San Diego, California
Listed
Apr 12, 2006
Sector
Health Care
Industry
Biotechnology
Website
gyretx.com

GYRE key statistics

Market cap
654.23M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
153.65K
Volume
242.07K
Open price
$6.08
High today
$6.34
Low today
$6.08
52 Week high
$9.14
52 Week low
$5.44

Gyre Therapeutics (GYRE) at a glance

Gyre Therapeutics (GYRE) last traded at $6.17, with a market cap of 654.23M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $6.08 and $6.34. The current price is 1.5% above the day's low and 2.7% below its high.

Volume so far is 242.07K shares, above the average of 153.65K shares a day.

Over the past year Gyre Therapeutics has ranged from $5.44 to $9.14, and now sits 20% of the way up that range.

Gyre Therapeutics met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported -$0.12 per share against an estimate of -$0.0918.

GYRE earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 117.0% on average.

  1. Q3 FY23: reported -$1.05 per share against an estimate of -$0.765
  2. Q4 FY24: reported -$0.0012 per share against an estimate of $0.0408
  3. Q1 FY25: reported $0.03 per share against an estimate of $0.0306
  4. Q2 FY25: reported $0.02 per share against an estimate of $0.0306
  5. Q3 FY25: reported $0.08 per share against an estimate of $0.0272
  6. Q4 FY25: reported $0.05 per share against an estimate of $0.0578
  7. Q1 FY26: reported -$0.045 per share against an estimate of -$0.0748
  8. Q2 FY26: reported -$0.12 per share against an estimate of -$0.0918

GYRE news

  • Vandana Singh

    Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker

  • Avi Kapoor

    MAC Copper, ATS, Pony AI And Other Big Stocks Moving Higher On Tuesday

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

  • Avi Kapoor

    Applied Therapeutics, PowerFleet, VF Corp, Victoria's Secret And Other Big Stocks Moving Higher On Wednesday

Similar companies

Companies in the same industry as Gyre Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.